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Introduction: Generally agreed outcome criteria in psycho-
sis are required to evaluate the effectiveness of new treat-
ment strategies. The aim of this study is to explore clinical
recovery in first-episode patients, defined by meeting crite-
ria for both symptomatic and functional remission.
Method: In a sample of first-episode patients (N 125),
symptomatic and functional remission during the last
9 months of a 2-year follow-up period were examined, as
well as recovery and its predictors. Results: Half the
patients (52.0%) showed symptomatic remission and
a quarter (26.4%) functional remission, while one-fifth
(19.2%) met both criteria sets and were considered recov-
ered. Recovery was significantly associated with short
duration of untreated psychosis and better baseline func-
tioning. Conclusion: Most functionally remitted patients
were also symptomatically remitted, while a minority of
symptomatically remitted patients were also functionally
remitted. Treatment delay may affect chance of recovery.
Key words: schizophrenia/remission/social functioning/
disability/duration of untreated psychosis
Introduction
From Kraepelin’s times, schizophrenia has been primar-
ily considered as a ‘‘deficit state,’’ and this view persisted
into modern diagnostic systems by including functional
deteriorationasadiagnosticcriterionofschizophrenia.
1,2
However, functional deterioration may be absent in cases
previously meeting criteria for schizophrenia and may be
present across diagnostic borders, eg, in cases of bipolar
disorder. Indeed, modern insights into the pathogenesis
of schizophrenia point out that this disorder consists
of subgroups with differential course and outcome.
3–5
Thus, the degree of functional deterioration should be
considered a dependent variable of yet largely unknown
risk factors instead of being implied in schizophrenia by
definition. As a consequence, standardized tools for out-
comemeasurement,includingassessmentofrecovery,are
needed in schizophrenia outcome research and to find
predictorsofprognosis.Atpresent,therearenogenerally
accepted outcome criteria in psychosis.
6 Recently, how-
ever, the Remission Working Group proposed standard-
ized criteria for symptomatic remission.
7 A next step
would be to define criteria for recovery. According to
the Remission Working Group and leaders in the field,
recovery in schizophrenia would imply not only being
free of psychopathology but also the ability to function
in the community, socially, and vocationally.
7–9 Symp-
tomatic remission thus is a prerequisite to recovery but
may not be sufficient.
1 On the other hand, some patients
may experience functional remission despite their ongo-
ing symptoms.
10–12 The aim of the present study is to
examine symptomatic and functional remission as 2 con-
stituents of clinical recovery in a sample of first-episode
patients. The present study is a further follow-up of the
data collected in the Medication Strategies in First Onset
Schizophrenia (MESIFOS) trial.
13 Data on symptomatic
remission in this sample were recently published in this
journal.
14
Conceptualization of Recovery and Symptomatic and
Functional Remission
The view of the Remission Working Group that symp-
tomaticremission is astepping stone toward the morede-
manding state of recovery, obtainable by many people
over time, represents a significant step away from erro-
neous professional defeatism. However, this concept of
recovery falls short of satisfying the demands of patients
and their families. Consumers have developed their own
experience-based approach to schizophrenia, leading to
a quite different concept of recovery. The latter concept
of recovery, described by consumer advocates, rehabili-
tation practitioners, and researchers, refers to a unique
and personal process ‘‘in which people are able to live,
work, learn, and participate fully in their communities’’
and ‘‘to live a fulfilling and productive life despite a dis-
ability.’’
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ery to the comprehensive care of chronically and persis-
tently mentally ill adults.
18 As Davidson et al
19
perspicuously state, this second concept of recovery is
even applicable to people who do not recover in the clin-
ical sense. These authors coined the term of being ‘‘in re-
covery’’ for this concept as opposed to ‘‘recovery from’’
schizophrenia. Being ‘‘in recovery’’ then does not reflect
a clinical or scientific reality as much as it does a personal
experiential one. This concept is about reclaiming auton-
omy and self-determination without first having to clin-
ically recover from an illness. This article however is
restricted to the clinical model of recovery because our
data only allow analysis of these aspects. This narrow,
clinical definition of recovery is in agreement with the
concept of recovery proposed by the Remission Working
Groupandleadingauthoritiesinthefield,butitshouldbe
noted that this clinical concept does not by any means re-
place or rule out the consumer perspective on recovery.
7,8
Another issue is whether recovery should demand not
only symptomatic and functional remission but also the
absence of medication.
8,20 However, there is overwhelm-
ing evidence that continued use of antipsychotics pre-
vents symptomatic relapse and is almost a necessity for
sustaining a high level of functioning among persons di-
agnosed with schizophrenia.
21,22 To account for this fact
and to increase the practicability of the recovery concept,
continued use of antipsychotics should be allowed.
8 The
need for medication thus distinguishes the concept of re-
covery from cure. This is consistent with the view of the
field, and it has also been noted for depression that main-
tenance medication should not be seen as an obstacle to
recovery.
8,23 Although neurocognitive functioning is also
an important dimension to be included in operational
citeria for recovery, neurocognition was beyond the
scope of the parent study. Neurocognitive data therefore
were not available.
Symptomatic Remission
Criteria for symptomatic remission were adopted from
Andreasenet al.
7In accordance,thePositive andNegative
Syndrome Scale (PANSS) was used to assess the relevant
symptoms: P1 (delusions), P2 (conceptual disorganiza-
tion), P3 (hallucinatory behavior), N1 (blunted affect),
N4 (social withdrawal), N6 (lack of spontaneity), G5
(mannerisms/posturing), and G9 (unusual thought con-
tent). All relevant item scores have to be 3 (mild) or less
on a scale ranging from 1 (not present) to 7 (severe). Dur-
ing a certain observational period (according to Andrea-
sen et al,
7 6 mo; in this study, 9 mo), patients have to be
monitoredforsymptomaticrelapse.Symptomaticrelapses
are thendefinedas an exacerbationofsymptoms duringat
least 1 week with at least one relevant PANSS item score
above 3 (mild). No symptomatic relapses are allowed dur-
ing the agreed observational period.
Determining Functional Remission: The Assessment of
Social Functioning
According to generally accepted views, functional remis-
sion implies proper social functioning in the main
domains of every day life: personal care, living, working,
and relating to others. However, the assessment of social
functioning is quite complicated.
24–26 Many instruments
have the drawback of assessing a mixture of instrumental
performance of daily life tasks and psychopathology-
related behavior instead of measuring the level of func-
tioning in social roles relative to what one may expect
based on social position and background. To meet the
latter demands, the Groningen Social Disabilities Sched-
ule (GSDS) has been developed in the context of the In-
ternational Classification of Impairments, Disabilities
and Handicaps
27 and the International Classification
ofFunctioning,DisabilityandHealth.
28TheGSDSrelies
on the sociological framework of social role theory.
29–32
In these World Health Organization (WHO) classifica-
tions, a social disability is defined as a deficiency in
the ability to perform activities and manifest behavior
as would be expected in the context of a well-defined so-
cial role. It is important to note that social role function-
ing has to be measured against normative expectations in
a certain cultural context. The reference group consists of
people from the same cultural background in a compara-
ble position, and the assessment incorporates expecta-
tions of key figures in the individual’s inner circle.
Social disabilities are assessed by means of a semistruc-
tured investigator-based interview measuring social func-
tioning and adjustment over the last 4 weeks in 8 social
roles, 7 of which are included in this study (see table 1).
Thebaselinemeasurement wasrelated tothe1-monthpe-
riodjustbeforethefirstmentalhealthcontact.Theparen-
tal role was left out because of limited applicability.
Adisabilityisratedbytheinvestigatorona4-pointscale
from no (0), minimal (1), obvious (2), and serious (3) dis-
ability.Thescoresoneachrolehaveanchorpoints,describ-
ing the nature and severity of the corresponding problems
withcriteriafor(a)thefrequencyanddurationofthefunc-
tionaldeficits,(b)the damageinflicted tothe individualor
toothers,and(c)theneedforhelp.Atotaldisabilityscoreis
calculatedbycombining7rolescores,rangingfrom0to21.
Thepsychometricqualities ofthescalehavebeenreported
to be good.
30–32 The GSDS also yielded reliable results
in cross-national research studies. Factor analysis and
item response scaling underlined the validity of a one-
dimensionaloverallroledisabilityscale(Mokkenanalysis:
H = 0.48, rho = 0.79, and delta = 19.03)
29,33.
An important question is how to define appropriate
thresholds in social role functioning scores that corre-
spond to functional remission. Because many people
who do not suffer from schizophrenia have persistent
social deficits, patients recovering from schizophrenia
cannot be expected to have no social impairments at
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363all. Therefore, minor impairments (in work or in social
and intimate relationships) were allowed to be present
in functional remission, if not leading to significant im-
pairment to perform in any of the 7 roles. A functionally
remitted patientshouldfunction adequatelyin all 7social
roles with none or only a minimal disability in any of
them (not allowing a score of 2 or 3 on any GSDS
role). Just like symptomatic remission, functional remis-
sion should be monitored. Because of the time course of
fluctuation of functioning levels, biweekly monitoring is
frequent enough to show whether functional remission
was sustained during an observational period of, eg,
9 months.
Operational Criteria for Recovery
We explore recovery criteria based on 2 dimensions:
symptomatic remission and functional remission, which
should be sustained during a prolonged period. In this
study, the last 9 months of a 24-month follow-up period
after first treatment response were chosen as the observa-
tional window through which social functioning and
symptomatology were monitored to establish the occur-
rence of recovery status. This 9-month observational
window is relatively short compared with most other
recovery studies covering periods of 2–5 years and
even longer.
34 While these long-term studies are needed
to explore sustained recovery, the short observational
window in our study enabled close monitoring. This issue
is further discussed in the Discussion section of this arti-
cle. The 9-month observational window was determined
by the original MESIFOS design and therefore is rather
arbitrarily.
Methods
Patient Sample
The patients were recruited as part of the MESIFOS
study.
13 They were first-episode patients, aged 18–45
years, who had never been treated before, and who con-
sented to be randomized to either maintenance antipsy-
chotics or guided discontinuation strategy if they showed
a sufficient response of positive symptoms (maximum of
1 score of 4 on positive subscale of PANSS) and did not
relapseduring6monthswithinthefirstyearoftreatment.
The operational criteria for first episode were: first epi-
sode of uninterrupted positive symptoms, no matter
the duration, no symptom remission for 1 month or lon-
ger duration, and no antipsychotic treatment for more
than3months.Fulfillmentwasdeterminedduringadiag-
nostic interview using items from the Interview for Ret-
rospective Assessment Of Schizophrenia (IRAOS) and
confirmed using the Schedules for Clinical Assessment
in Neuropsychiatry (SCAN).
35,36 Patients were asked
to participate as soon as they were able to understand
the consequences of participation, usually around the
time of the first response of positive symptoms. Recruit-
ment took place from October 2001 through December
2002 in a catchment area of 3.1 million inhabitants in
the north, east, and southwest of The Netherlands.
37 Af-
ter obtaining written informed consent, the patients were
diagnosed using the SCAN interview. Only patients with
schizophrenia and other nonaffective psychotic disorders
were included.
Of 257 treatment-naive first-episode patients who met
the study criteria 149 (58%) gave written informed con-
sent. Two patients committed suicide, and 106 patients
refused any participation. There were no differences be-
tweenparticipantsandnonparticipantsregardinggender,
age at first contact, marital status, living situation,
Table 1. Social roles, personal situations, and corresponding role
dimensions of the GSDS
Social Role
Personal
Situations
Role
Dimensions
Self-care —personal hygiene;
physical care
—looks and appearance;
manners
Housekeeping Living together —social activities
—economic contribution
Living alone —independent living skills
—economic independency
Family
relationships
—emotional relationship
with parents
—frequency of contacts
with parents
—emotional quality and
frequency of contacts
with siblings
partner
relationships
Having a
partner
—emotional ties
—sexual relationship
Being single —adequacy of dating
activities
Community
integration
—interest in social
environment
—participation in social
events, clubs
—being considerate of
others
Relationship with
peers
—quality of contacts
—frequency and number
of contacts
Vocational role Working, studying —daily routine
—Working performance
—contacts with colleagues
—goal-directedness of
activities
Housekeeping —daily routine
—performance
—goal-directedness of
activities
Unemployed —goal-directedness of
activities
Retired —goal-directedness of
activities
364
L. Wunderink et al.and illicit drug use. Of the 149 patients who were willing
to participate 18 patients were not included in the
medication strategies study: 1 patient committed suicide,
9 patients relapsed within 6 months after response,
8 patients did not respond with adequate positive symp-
tom reduction within 6 months of antipsychotic treat-
ment, 3 patients withdrew informed consent during
follow-up, and of another 3 patients PANSS data
were missing. This left 125 patients to be included in
the present study.
14
Predictors of Recovery
Inordertoexaminetheassociationofconceivablepredic-
tors of outcome with recovery, we recorded gender, du-
ration of untreated psychosis (DUP), time to response
(TTR) of positive symptoms, baseline psychopathology
(PANSS), social functioning (GSDS), quality of life
(WHOQoL-Bref), use of illicit drugs (SCAN interview),
and living situation (living alone vs with others). DUP
was assessed during the SCAN interview and defined
bythetimebetweenthefirstmanifestationofanypositive
psychotic symptom and the start of antipsychotic treat-
ment. TTR was defined by the time from the start of an-
tipsychotic treatment until first treatment response.
37
Quality of life was assessed at baseline with the WHO-
QoL-Bref, a 26-item self-report questionnaire, compris-
ing satisfaction with health, psychological functioning,
social relationships, and environmental opportunities,
as experienced over the last 2 weeks. Each item is scored
on a 5-point scale, higher scores indicating better quali-
ty of life. We will present the total score, ranging from
26 to 130.
38
Follow-up Assessments and Monitoring
Psychopathology (PANSS) and quality of life (WHO-
QoL-bref) were assessed 6, 15, and 24 months after
response and social role functioning (GSDS) at 15 and
24 months. In addition, the patients were monitored bi-
weeklybytheirclinicians,checkingsymptomseveritylev-
els as well as levels of functional impairment. In case the
clinician observed a symptomatic or functional relapse,
these were confirmed or refuted by PANSS and GSDS
scores rated by members of the research team. Patients
were considered to be recovered if at both assessments
PANSS criteria for remission according to Andreasen
et al
7 were fulfilled and GSDS role functioning scores
were  1, without symptomaticor functionalrelapsedur-
ing the observation period.
Training and Reliability
Psychiatrists who were trained by the Groningen WHO
Training Center administered the SCAN interview.
Training for PANSS and GSDS was provided at inves-
tigator meetings, supplemented by written training mate-
rials. Training for the PANSS and GSDS included rating
of a videotaped interview, followed by discussion and re-
view of ratings. Regular booster meetings were organized
to maintain interrater reliability. Reliability of the GSDS
was established by 12 raters all rating the same 11 sub-
jects. We used another 12 subjects, all rated by 11 raters,
to establish the reliability of the PANSS. We calculated
weighted kappas for each GSDS item. The square
weighted kappa scores ranged from 0.55 to 0.88 for
each GSDS item, with a mean of 0.67. The 2-way
mixed-model intraclass correlation coefficient (ICC)
was used to assess the reliability of the PANSS scales.
The ICC for the PANSS subscale of positive symptoms
was .84 and for the subscale of negative symptoms .83.
Statistical Analysis
Analyses were carried out with the statistical package
SPSS (version 14; SPSS Inc, Chicago, IL). The associa-
tion of symptomatic remission with functional remission
was analyzed with a Fisher Exact test. Differences be-
tween baseline characteristics of recovered and not-
recovered patients were analyzed using Student t tests
for continuous variables and Pearson chi-square tests
for categorical variables. Nonparametric tests (Mann-
WhitneyUtests)wereappliedforDUPandTTRbecause
of their positively skewed distribution. A linear mixed-
models repeated-measures analysis of covariance was
used to analyze the relation between recovery and re-
peatedquality-of-lifemeasurements. Thedependentvari-
able was WHOQoL-bref total score. Fixed effects were
recovery status, time (assessments T0, T6, T15, and
T24), and the interaction of recovery status and time.
The general covariance matrix (unstructured) was speci-
fied for the covariance structure of the residuals of the
repeated measurements. The subjects (the observational
units in the analysis) were included as a random effect.
The type III method to calculate the sums of squares
of the fixed effects in the model was applied. To find
factors predicting recovery, a binary logistic regression
analysis with backward selection was applied with recov-
ery as the dependent variable and the factors significantly
associated with recovery in the bivariate analyses as
independent variables.
Because of its skewed distribution, DUP was log
transformed in this analysis.
Results
Baselinecharacteristicsofthesampleareshownintable2.
The development over time of the PANSS subscale
scores, the GSDS total scores, and the WHOQoL-bref
total scores in recovered and nonrecovered patients are
shown in table 3.
A mixed-models analysis shows that quality of life in
recovered patients is slightly but statistically significantly
betterthaninnot-recoveredpatientsfromthestart(df =1,
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Clinical Recovery in First-Episode PsychosisF = 11.3, P < .001) and that there is significant im-
provement over time in both groups (df = 3, F = 8.8,
P < .001) but equally in recovered and not-recovered
patients (df = 3, F = 0.4, P = .740). A cross-tabulation
of functional remission against symptomatic remission
(table 4) shows the contribution of both outcome
domainstorecovery.Recoveryisachievedby24patients.
There was no relationship between recovery and the arm
(maintenance vs discontinuation strategy) in the original
trial (Fisher Exact test: P = .5). The same applies for
symptomatic and functional remission. Of all patients
showing functional remission, 72.7% met criteria of re-
covery, but only 36.9% of all patients with symptomatic
remission did. The odds ratios to achieve vs not to
achieve recovery were 2.7 for functional remission and
0.6 for symptomatic remission. A Fisher Exact test (2-
sided) showed a significant association between symp-
tomatic remission and functional remission (P = .008).
Bivariate analyses demonstrated that recovered
patients already differed significantly at baseline from
nonrecovered patients. The mean DUP in recovered
patients was 31.8 days, compared with 320.9 days in non-
recovered patients (Mann-Whitney Z score of  3.407,
P = .001). Recovered patients had less severe baseline
positive (t = 2.053, P = .042), negative (t = 2.177,
P = .031), and general symptoms (t = 2.288, P = .024)
on the PANSS subscales and less social role performance
disability on baseline GSDS total scores (t = 3.530,
P = .001). Recovered patients also were less often ini-
tiallydiagnosedwithschizophrenia:only8.8%ofpatients
with a schizophrenia diagnosis (n = 57) recovered com-
pared with 27.9% of patients with other nonaffective psy-
choses (n = 68); (Fisher Exact test, 2-sided, P = .011).
There was no significant difference between recovered
and nonrecovered patients regarding gender, baseline
quality of life, TTR, living alone vs with others, or base-
line diagnosis of cannabis abuse. To examine the relative
contribution to recovery of the factors that were associ-
ated with recovery in the bivariate analyses, we tested a
logistic regression model with backward selection. Re-
covery was entered as the dependent variable, and base-
line PANSS positive, negative, and general symptom
subscale scores; baseline GSDS total score; and DUP
(log transformed) were entered as independent variables.
Schizophrenia diagnosis was left out because of its inter-
dependency with DUP because a baseline diagnosis of
schizophrenia implied a minimum duration of illness
before treatment of 6 months. The only significant pre-
dictors of recovery that remained were DUP (odds ratio
[OR] = 0.531, df = 1, P = .008) and baseline GSDS total
score (OR = 0.858, df = 1, P = .021).
The mean daily dose of antipsychotics during follow-
up did not differ between recovered and not-recovered
patients.Mostprescribeddrugswererisperidone,olanza-
pine, quetiapine, and clozapine, with a mean duration of
prescription per patient of 5.6, 5.3, 1.6, and 0.8 months,
respectively. The mean daily dosages were risperidone
2.7 mg, olanzapine 10.4 mg, quetiapine 541 mg, and
clozapine 336 mg. Patients were treated according to
the guidelines, including psychoeducation, family inter-
ventions, and case management.
Table 3. Psychopathology, Role Functioning, and Quality-of-Life Measurements Over Time in Recovered (R) and Not-Recovered (NR)
Patients
T0 T6 T15 T24
R, Mean
(SD)
NR, Mean
(SD)
R, Mean
(SD)
NR, Mean
(SD)
R, Mean
(SD)
NR, Mean
(SD)
R, Mean
(SD)
NR, Mean
(SD)
PANSS positive subscale total score 9.2 (2.5) 10.6 (3.0) 8.4 (1.4) 9.4 (2.4) 8.6 (2.1) 10.4 (3.5) 8.7 (1.9) 11.4 (4.3)
PANSS negative subscale total score 11.6 (5.5) 14.1 (5.0) 10.0 (3.6) 13.6 (4.7) 8.4 (2.0) 13.3 (5.1) 8.5 (2.0) 13.7 (5.9)
PANSS general subscale total score 23.2 (6.4) 26.6 (6.5) 21.0 (4.2) 24.2 (6.3) 19.2 (3.4) 24.7 (7.0) 20.6 (4.9) 25.8 (7.0)
GSDS total score 6.3 (3.1) 9.1 (4.7) NA NA 1.8 (1.5) 6.7 (3.9) 1.9 (1.7) 6.5 (3.9)
WHOQoL total score 93.6 (11.9) 91.2 (12.4) 93.1 (9.0) 89.2 (10.5) 101.1 (9.5) 94.7 (13.0) 102.0 (10.6) 96.3 (13.3)
Note:T 0= baseline assessment, T6 = assessment after 6 months, T15 = assessment after 15 months, T24 = assessment after 24 months,
R = recovered, NR = not-recovered, PANSS = Positive and Negative Syndrome Scale, GSDS = Groningen Social Disability Schedule,
WHOQoL (higher scores better QoL) = World Health Organization Quality-of-Life Scale, NA = Not Applicable.
Table 2. Baseline Characteristics of the Sample (N = 125)
Characteristic n (%)
Male gender 86 (68.8)
Age at onset of psychosis, y, mean (SD) 25.7 (6.7)
Duration of untreated psychosis,
days, mean (SD) [median]
265 (535)
[31]
Age at start of treatment, y, mean (SD) 26.4 (6.4)
Time to response, d, mean (SD) [median] 75.9 (52.9) [61.0]
Living alone 46 (36.8)
Married or cohabiting 19 (15.2)
Schizophrenia 57 (45.6)
Other nonaffective psychosis 68 (54.4)
Cannabis dependence/abuse 30 (24.0)
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a group showing neither functional nor symptomatic re-
mission (41%) and a groupshowingremission in only one
of the 2 domains (40%). There were no significant base-
line differences between the latter 2 groups.
Discussion
About 20% of the included sample of first-episode
patients met the proposed criteria for recovery at the
end of a 2-year follow-up period. Taking into account
the 18 patients who consented but were not included be-
cause they did not respond, relapsed early, or committed
suicide, this percentage would be about 17. This may
seem a small proportion of patients, but the proportion
of patients meeting recovery criteria may well increase
with the duration of follow-up.
39 The proposed criteria
of recovery are a combination of the symptomatic remis-
sion criteria recently proposed by Andreasen et al
7 and
a criteria set relating to social role functioning. The latter
set has been based on the GSDS, designed to normatively
quantify social role functioning accounting for age, gen-
der, and sociocultural background. This procedure is in
accordance with the operational definition of recovery
proposed by Liberman et al.
8 The GSDS has the advan-
tage of anchor points for each role and an established re-
liability and validity. The thresholds in the separate role
functioning scores have been chosen such as to allow for
minimalimpairmentsinanyrole.All7roleswereallowed
to have a score of at most 1. This implies that patients
whomeetthesedemandsarefunctioningprettywellwith-
out apparent impairments.
Limitations
A substantial number of first-episode patients who were
to be included refused to participate. There were however
no indications of differences between included and not
included patients. Almost all patients who were willing
to participate (n = 149) were actually included
(n = 131; 87.9%). These figures are consistent with
the results of other studies.
40,41 However, due to the
18 patients not meeting the criteria of the parent
study, the 20% recovery rate of the included sample
may overestimate the recovery rate for the entire sample.
Another major limitation is the lack of neurocognitive
data. Neurocognitive deficits might be present already
at baseline and might predict nonrecovery and functional
impairment.
Symptomatic Remission, Functional Remission, and
Recovery
About two-thirds of the patients who had a symptomatic
remission did not also function properly, while most
patients who functioned well were also free from symp-
toms. Symptomatic remission by definition is a prerequi-
site to recovery, but it is not sufficient. Moreover,
functional improvement does occur in a small minority
of patients who are not free from symptomatology.
This is consistent with findings in other studies.
10,12 It
appeared that subjective quality of life did not differen-
tiate between recovered and nonrecovered patients if tak-
ing into account their baseline ratings. This means that
patient reported well being may be not a determining
or discriminating factor of outcome of recovery in
schizophrenia.
Time Frame of Recovery
Thetimecriterion(inthis study,9mo)is anarbitrary cut-
off. However, a shorter period would be insufficient to
implement regained functional capacities in daily life
and to permit validation of sustained and stable improve-
ment. A 9-month period seems to be long enough to be
meaningfulfromaclinical perspective andhasthe advan-
tage of enabling close monitoring, providing a solid base
forlongertermoutcomesresearch.Indeed,astrongpoint
inthedesignofourstudyistheclosemonitoringofsymp-
tomatology and social functioning by clinicians during
the observational period of 9 months. Long-term studies
(2–5y)areneededtostudysustainedrecoveryoverlonger
periods of time. Studies on longer term recovery propose
time frames of 2 years and more.
34 As a consequence, re-
covery criteria in these studies have been more globally
defined and less severe (eg, Global Assessment of Func-
tioning scores of above 60). Because quite a number of
patients will move from recovery to a nonrecovered state,
and back,
9 longer time frames will exclude more patients
who relapse, and less patients will meet a longer term
recovery criterion. However, the 20% of recovered
patients in our study is rather low compared with most
long-term studies that find percentages of 40% and
more. This is probably due to the combination and the
severity of symptomatic and functional remission criteria
in our study.
4,5 In the present study, being recovered
would mean to have regained a formerly expected level
of day-to-day functioning, while symptoms have been
stably mild or absent, and this has been sustained during
the 9 months of observation.
Table 4. Cross-tabulation of Symptomatic Remission Against
Functional Remission
Symptomatic
Remission, n (%)
Total n (%) No Yes
Functional remission, N (%)
No 51 (40.8) 41 (32.8) 92 (73.6)
Yes 9 (7.2) 24 (19.2) 33 (26.4)
Total n (%) 60 (48.0) 65 (52.0) 125 (100.0)
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DUP and baseline social functioning were the only fac-
torsthatindependentlypredictedrecoveryafter2yearsof
follow-up. No recovery occurred in patients with DUP of
6 months and longer. DUP has been shown to predict
various outcome parameters by many other studies.
37,42
Though not as strong as DUP, social role functioning be-
fore treatment also is an index of better recovery chances.
As a corollary of less compromised mental functioning, it
may be associated with a better prognosis.
Diagnostic Inclusion Criteria
The patient sample included in this study consisted of
a catchment area based cohort of first-episode patients
diagnosed with nonaffective psychosis. The patients
were diagnosed at baseline, shortly after coming into
treatment. The median DUP in our sample was 31
days,andasaconsequencemanypatientswerediagnosed
very shortly after their first break of psychosis. The sam-
ple thus includes psychoses of limited duration and offers
a view into the prognosis of first break psychosis. The
present study meets an important requirement for studies
into the prognostic features of a group of disorders, such
as the schizophrenia-like psychoses: these studies should
include first episodes of all nonaffective psychoses and
not preselect a sample by its protracted course character-
istics, such as implied by the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, schizophre-
nia criteria. Despite this early time of diagnosis, 57
patients (45.6%) were assigned to a diagnosis of schizo-
phrenia, as a consequence of duration of illness of at least
6 months before coming into treatment.
Further Research
Follow-up is needed to register the patient flow transiting
from nonrecovered states into recovery status and back.
Patients showing functional remission without symptom-
atic remission deserve special attention. These patients
apparently are on the edge of recovery and may take ad-
vantageoftargetedapproachesforpersistingorrelapsing
symptoms. A number of them may not be bothered by
their symptoms, consistent with the finding of psychotic
symptomatology in the general population.
43
The criteria for recovery presented here are meant to
serve a heuristic purpose. They are particularly interest-
ing from a clinical point of view and do not acknowledge
the consumer perspective on recovery. They will have to
show their value in clinical practice with respect to long-
term outcomes and stability over time. Our results clearly
showthatsocialfunctioningis animportantparameterin
schizophrenia outcome research, both as a predictor of
futurecourse characteristicsand as amore selective index
of recovery than symptom remission.
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